Skip to main content

Table 2 Factors associated with detection of ceftriaxone-resistant Enterobacteriaceae colonization among 561 patients without ceftriaxone-resistant Enterobacteriaceae colonization at enrollment

From: Drug-resistant Enterobacteriaceae colonization is associated with healthcare utilization and antimicrobial use among inpatients in Pune, India

Risk Factor, n (%)

Ceftriaxone-resistant Enterobacteriaceae colonization, n (%)

Unadjusted OR (95% CI)

p-value

Adjusted ORa (95% CI)

p-value

No acquisition, N = 512

Acquisition, N = 49

Age in years

  < 5

163 (32)

21 (43)

4.7 (1.3–29.9)

0.04

4.4 (1.2–28.7)

0.06

 5–11

88 (17)

5 (10)

2.1 (0.4–14.8)

0.39

2.0 (0.4–14.6)

0.41

 12–23

73 (14)

2 (4)

Ref

Ref

Ref

Ref

 24–59

154 (30)

15 (31)

3.6 (1–22.9)

0.1

3.8 (1–24.9)

0.08

  ≥ 60

34 (7)

6 (12)

6.4 (1.4–45.5)

0.03

7.0 (1.5–50.1)

0.02

 Male sex

307 (60)

33 (67)

1.4 (0.7–2.8)

0.36

1.5 (0.8–2.9)

0.23

 Income < 5000 INR / month

183 (36)

23 (47)

1.6 (0.0–8-3)

0.12

  

 Farmer or laborer

203 (40)

24 (49)

1.5 (0.8–2.7)

0.22

  

 HIVb

56 (22)

6 (27)

1.3 (0.4–3.7)

0.6

  

 ICU

102 (20)

17 (35)

2.1 (1.1–4.1)

0.03

1.6 (0.8–3.4)

0.18

Pre-hospital antibiotic use

 Within the past week

99 (19)

13 (27)

1.5 (0.7–3.0)

0.26

  

 Within the past month

121 (24)

14 (29)

1.3 (0.6–2.6)

0.48

  

Initial inpatient antibiotic Rx

 Any antibiotic

432 (84)

45 (92)

2.1 (0.7–8.2)

0.21

  

 Multiple antibiotics

240 (47)

30 (61)

1.8 (0.9–3.5)

0.07

  

 3rd-gen cephalosporin

234 (46)

35 (71)

3.0 (1.5–6.1)

< .01

2.9 (1.5–5.8)

< 0.01

 Fluoroquinolone

19 (4)

1 (2)

0.5 (0.0–3.6)

1

  

 Macrolide

96 (19)

13 (27)

1.6 (0.7–3.2)

0.19

  

 Aminoglycoside

53 (10)

8 (16)

1.7 (0.6–3.9)

0.23

  
  1. OR odds ratio, IQR interquartile range, ICU intensive care unit, INR Indian rupees, Rx prescription
  2. aAdjusted for age, sex, ICU admission, and third generation cephalosporin initial antibiotic prescription
  3. bHIV test results were available for 249 patients without ceftriaxone-resistant Enterobacteriaceae acquisition and 22 patients with ceftriaxone-resistant Enterobacteriaceae acquisition